Senvest Capital
Senvest Capital operates as a holding company with a focus on investment management and direct investments in public securities and private ventures. Established in 1997 and headquartered in Montreal, Canada, Senvest engages in a diverse range of investment activities, primarily targeting value stocks in public equity markets. It employs various analytical methods, including fundamental and quantitative analysis, to guide its investment decisions. Additionally, Senvest holds and manages a portfolio of equity and real estate investments, primarily in the United States, with some interests in self-storage properties in Spain and real estate in Argentina. The company has a historical background as a distributor of Sensormatic Electronics, a pioneer in retail security systems, and has previously developed one of Canada’s first cable pay-TV channels. Senvest Capital's operations extend to managing separate client-focused portfolios, catering to both institutional clients and high net worth individuals.
Top Stages
8 past transactions
Breakthrough
Pre Seed Round in 2025
Breakthrough is a technology company that specializes in transforming the sales process. It develops an artificial intelligence (AI) powered platform designed to enhance business-to-business (B2B) storytelling for sales and marketing teams. The platform creates customized content for various communication channels, enabling marketing and sales teams to collaborate and deliver tailored, relevant pitches at scale. This approach aims to improve response rates and drive business growth by making sales interactions more personalized and effective.
Bigfoot Biomedical
Series C in 2020
Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.
Bigfoot Biomedical
Series B in 2018
Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.
Bigfoot Biomedical
Series B in 2017
Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.
Unlimited
Seed Round in 2017
UNLIMITED is at the forefront in the design and creation of high-end Virtual Reality Experiences. VR is a revolutionary new medium - a mind-blowing hybrid between interactive media and immersive cinematic experiences. They offer branded and original VR content for immersive and interactive media, including films, TV series, games and advertising.
Bigfoot Biomedical
Series A in 2016
Bigfoot Biomedical, Inc. is a medical device company focused on transforming diabetes care for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company specializes in developing an integrated diabetes management system that features cloud connectivity and human-centered automation. This system optimizes insulin dosing and delivery through a combination of automated infusion pumps and connected insulin pen options. Bigfoot Biomedical's innovative approach employs machine learning and user-friendly technologies to alleviate the cognitive, emotional, and financial burdens associated with insulin-requiring diabetes. By offering a comprehensive digital drug delivery platform through a unique monthly subscription service model, the company aims to enhance the quality of life for patients managing their diabetes.
Spotify
Series G in 2015
Spotify, headquartered in Stockholm, Sweden, is a global music streaming service provider. As of 2023, it has 602 million monthly active users. The company offers on-demand access to songs across various devices, enabling users to search, discover, and share music. It also provides artists with tools to share their work and promote their careers. Spotify generates revenue through a paid subscription model, known as Spotify Premium, and an ad-supported service. In 2023, these models contributed to 86% and 14% of its total revenue, respectively.
Medigus
Post in 2014
Medigus Ltd. is a medical device company based in Omer, Israel, focused on developing, manufacturing, and marketing minimally invasive endo-surgical tools and direct visualization technology. Founded in 1999, the company is known for its flagship product, the Medigus Ultrasonic Surgical Endostapler (MUSE) system, which provides a single-use device for the incisionless treatment of gastroesophageal reflux disease (GERD). This innovative system integrates a miniaturized video camera, a surgical stapler, and ultrasonic alignment technology, enabling gastroenterologists and surgeons to perform endoluminal procedures that eliminate the need for traditional open or laparoscopic surgery. In addition to its GERD treatment solutions, Medigus designs and manufactures advanced endoscopy systems and micro video cameras for various medical and industrial applications, leveraging its proprietary technologies to support a wide range of endoscopic procedures.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.